Estimate of the cost per responder for treatment with biological therapies of moderate-to-severe plaque psoriasis in Colombia for first-year and maintenance periods

References

• Organization WH. Global report on psoriasis [Internet]. Geneva: World Health Organization; 2016 [cited 2023 March 28]. Available from: https://apps.who.int/iris/handle/10665/204417
   Google Scholar
• Boehncke W-H, Schön MP. Psoriasis. The Lancet [Internet]. 2015;386:983–994.
   PubMed Web of Science ®Google Scholar
• Wei J, Zhu J, Xu H, et al. Alcohol consumption and smoking in relation to psoriasis: a Mendelian randomization study. Br J Dermatol. 2022;187:684–691.
   PubMed Web of Science ®Google Scholar
• Naldi L, Mercuri SR. Smoking and psoriasis: from epidemiology to pathomechanisms. J Invest Dermatol. 2009;129:2741–2743.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029–1072.
   PubMed Web of Science ®Google Scholar
• Pacifico A, Conic RRZ, Cristaudo A, et al. Diet-related phototoxic reactions in psoriatic patients undergoing phototherapy: results from a multicenter prospective study. Nutrients. 2021;13:2934.
   PubMed Web of Science ®Google Scholar
• Damiani G, Pacifico A, Russo F, et al. Use of secukinumab in a cohort of erythrodermic psoriatic patients: a pilot study. J Clin Med. 2019;8:770.
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DPM, Griffiths CEM, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385.
   PubMed Web of Science ®Google Scholar
• Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med (Lausanne). 2021;8. 10.3389/fmed.2021.743180.
   Web of Science ®Google Scholar
• Institute for Health Metrics and Evaluation. Global burden of disease study [Internet]. 2018 [cited 2023 March 28]. Available from: www.healthdata.org
   Google Scholar
• Armstrong AW, Betts KA, Signorovitch JE, et al. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. Curr Med Res Opin. 2018;34(7):1325–1333.
   PubMed Web of Science ®Google Scholar
• Porter ML, Kimball AB. Pharmacoeconomics of systemic and biologic therapy in dermatology. 2018.
   Google Scholar
• Bender R. Using and Interpreting adjusted NNT measures in biomedical research. Open Dent J. 2010;4:72–76. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944994/
   PubMedGoogle Scholar
• Ramaekers BLT, Robert WF, Pouwels X, et al. Ixekizumab for treating moderate-to-severe plaque psoriasis: an evidence review group perspective of a NICE single technology appraisal. Available from:Pharmaco Economics. 2018;36(8):917–927.
   PubMed Web of Science ®Google Scholar
• Instituto de Evaluación Tecnológica en Salud. Manual para la elaboración de evaluaciones económicas en salud [Internet]. 2014 [cited 2023 March 28]. Available from: www.iets.org.co
   Google Scholar
• Roberts FS. Measurement theory: with applications to decisionmaking, utility, and the social sciences [Internet]. Encyclopedia of Mathematics and its Applications. Cambridge: Cambridge University Press; 1984 [cited 2023 March 28]. Available from: https://www.cambridge.org/core/books/measurement-theory/7D75B72C3E5FA676EA7AD6AB4D8DF4A7
   Google Scholar
• Sawyer LM, Cornic L, Levin LA, et al. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol.2018. 33:355–366.
   PubMed Web of Science ®Google Scholar
• Yasmeen N, Sawyer LM, Malottki K, et al. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. J Dermatological Treat. 2022;33:204–218.
   PubMed Web of Science ®Google Scholar
• Loos AM, Liu S, Segel C, et al. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. J Am Acad Dermatol. 2018;79(1):135–44.e7.
   PubMed Web of Science ®Google Scholar
• Sawyer LM, Malottki K, Sabry-Grant Id C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLOS ONE. 2019;14(8):e0220868.
   PubMed Web of Science ®Google Scholar
• SbidianE CL. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. 2020. Available from www.cochranelibrary.com
   Google Scholar
• Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis a meta-analysis. JAMA Dermatol. 2020;156:258–269.
   PubMed Web of Science ®Google Scholar
• Manalo I, Gilbert K, Wu J. Time to raise the bar to psoriasis area severity index 90 and 100. J Eur Acad Dermatol Venereol. 2016;30:864–865. Blackwell Publishing Ltd.
   PubMedGoogle Scholar
• Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645–648. Blackwell Publishing Ltd.
   PubMed Web of Science ®Google Scholar
• Al Sawah S, Foster SA, Burge R, et al. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis. J Med Econ. 2017;20:1224–1230.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Foster SA, Zhu B, et al. Cost per additional responder associated with ixekizumab and etanercept in the treatment of moderate-to-severe psoriasis. J Med Econ. 2017;16:1246–1252.
   Google Scholar
• Núñez M, Huete T, de la Cueva P, et al. Evaluación de la eficiencia de los tratamientos biológicos en la psoriasis moderada a grave en España: análisis de coste por número necesario a tratar (NNT). Actas Dermosifiliogr. 2019;110:546–553.
   PubMed Web of Science ®Google Scholar
• Sawyer L, Fotheringham I, Wright E, et al. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. J Dermatological Treat. 2018;29:557–568.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Burge R, Malatestinic W, et al. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review. J Manag Care Spec Pharm. 2021;27(1):84–94.
   PubMed Web of Science ®Google Scholar
• Blauvelt Melinda Gooderham Christopher M Griffiths April W Armstrong Baojin Zhu Russel Burge Gaia Gallo Jiaying Guo Alyssa Garrelts Mark Lebwohl AE. Cumulative clinical benefits of biologics in the treatment of patients with moderate-to-severe psoriasis over 1 year: a network meta-analysis. Dermatol Ther (Heidelb). 2022;12(3):727–740.
   PubMed Web of Science ®Google Scholar